This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred > 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are currently in observation or undergoing bevacizumab maintenance treatment will be eligible to participate in the study.

Inclusion Criteria:

• Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred > 6 months after platinum-based chemotherapy
• This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
• Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
• Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
• Have a valid email address and access to the internet
• Provide voluntary written informed consent
• Speak and read English fluently

Exclusion Criteria:

• Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
• Another primary diagnosis of cancer in a different site

Patients with platinum-sensitive ovarian cancer in maintenance phase of second-line treatment